Sylvant

coronavirus nih

Sanofi, Regeneron cut severe patients in Kevzara COVID-19 study

Sanofi and Regeneron will refocus a phase 3 Kevzara study on critical COVID-19 patients after disappointing results in those not quite as ill.

Kyle Blankenship Apr 27, 2020 10:45am

coronavirus

Roche nabs $25M grant to accelerate Actemra trial for COVID-19

Apr 7, 2020 2:51pm

Concept of SARS-CoV-2 or COVID-19

EUSA Pharma opens COVID-19 trial for IL-6 inhibitor Sylvant

Mar 18, 2020 9:43am